20451 Seneca Meadows Parkway
About SenseonicsWe are a medical technology company focused on the design, development and commercialization of glucose monitoring systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our first generation continuous glucose monitoring, or CGM, system is a reliable, long-term, implantable CGM system that we have designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 days, as compared to five to seven days for currently available CGM systems.
CEO: Timothy T. Goodnow, PhD
CFO: R. Don Elsey
Chief Medical Officer: E. Lynne Kelley, M.D., FACS
54 articles with Senseonics
Patients Can Access Long-term Eversense CGM for only $99* Under Program
Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, reported financial results for the fourth quarter and full year ended December 31, 2018.
Senseonics is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes
Senseonics Holdings, Inc. announced the integration of Eversense CGM data into the Glooko diabetes data management platform.
Reports Preliminary Fourth Quarter and Full Year 2018 Revenue Results and Issues 2019 Financial Guidance
Now patients who need to have an MRI* do not need to remove the Eversense Sensor
Senseonics Holdings, Inc. today announced the appointment of Jon D. Isaacson as the company’s Chief Financial Officer, effective immediately.
Senseonics Announces First Study Participant Implanted in the U.S. as Part of the PROMISE 180-Day Sensor Clinical Study and the Submission of Key PMA Supplements to the FDA to Advance Current 90-Day Product
Senseonics Holdings, Inc. today announced that the extended life Eversense® XL sensor that lasts up to 180 days has been implanted in the first U.S. study participant as part of the clinical trial for pre-market application submission to the Food and Drug Administration.
Senseonics Holdings, Inc. today announced the retirement of Chief Financial Officer, R. Don Elsey. Mr. Elsey has agreed to remain in his current role and to step down when a replacement is appointed.
Senseonics Announces FDA Approval to Expand Eversense® CGM Certification to Nurse Practitioners and Physician Assistants
--Now all qualified healthcare providers can perform sensor placements on patients--
Senseonics Holdings, Inc. today announced that Aetna, the third largest commercial health plan provider in the United States, is providing coverage for Eversense, effective immediately.
Senseonics Holdings, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 8, 2018 at 4:30 p.m. Eastern Time
Senseonics Holdings, Inc. today announced that it plans to release its third quarter 2018 financial results after market close on Thursday, November 8, 2018.
Senseonics Holdings, Inc. reported financial results for the second quarter ended June 30, 2018.
Senseonics Begins U.S. Commercialization of Eversense Continuous Glucose Monitoring System With First Shipment, First Users and First Policy Coverage
Trained and authorized U.S. diabetes clinics begin providing the first-ever 90-day, long-term CGM system to people with diabetes
Senseonics Holdings, Inc. announced the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA.
Senseonics Holdings, Inc. Schedules Second Quarter 2018 Earnings Release and Conference Call for August 8, 2018 at 4:30 p.m. Eastern Time
Senseonics Holdings, Inc. announced that it plans to release its second quarter 2018 financial results after market close on Wednesday, August 8, 2018.
Senseonics Holdings, Inc. announced that it has commenced a registered underwritten public offering of $80 million of its shares of common stock.
FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes
The U.S. Food and Drug Administration today approved the Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to 90 days.
Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system
Senseonics Holdings, Inc. Schedules First Quarter 2018 Earnings Release and Conference Call for May 10, 2018 at 4:30 p.m. Eastern Time
Senseonics Holdings, Inc. announced that it plans to release its first quarter 2018 financial results after market close on Thursday, May 10, 2018.